Brain scan breakthrough: new tracer could catch Parkinson's early
NCT ID NCT06738862
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested a new radioactive tracer called [18F] - FD17 for PET imaging to detect clumps of a protein called alpha-synuclein in the brain. These clumps are linked to Parkinson's disease, multiple system atrophy, and a sleep disorder that often precedes Parkinson's. Researchers scanned 55 people, including healthy volunteers and patients, to see if the tracer could help diagnose these conditions earlier and more accurately. The goal is to improve early detection and diagnosis of neurodegenerative diseases.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- [18F] - FD17 (a radioactive imaging agent used in PET scans)
- What this could lead to
- If successful, this imaging method could allow doctors to detect Parkinson's and related diseases earlier and more accurately, potentially before symptoms worsen.
- What could go wrong
- This is a small, completed imaging study, not a treatment trial. The agent may not reliably distinguish between different diseases, and further larger studies are needed to confirm its usefulness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
55 people
The number who actually took part.
- Started
-
Dec 2024
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
10 PD subjects ,10 MSA subjects, 10 RBD subjects ,and 5 healthy control subjects
- Ages
-
45 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1: Normal cognitive function, CDR score=0(for healthy subjects) 2: Without neurological disorders, major chronic diseases, malignant tumors, or acute infectious diseases (for healthy subjects) 3: Without the family history of neurological disorders related to motor or cognitive impairments(for healthy subjects) 4: Clinical diagnosis of idiopathic PD (for PD patients) 5: Clinical diagnosis of MSA (for MSA patients) 6: Clinical diagnosis of idiopathic RBD (for RBD patients) 7: An informed consent form signed in writing by the subject or their legal guardian or caregiver. 8: Must be abled to be accompanied by nursing staff 9: Must be able to understand and sign a informed consent form before any evaluation and examination 10: Must have medical records to prove that they have undergone surgical sterilization (such as hysterectomy, bilateral oophorectomy, or tubal ligation) or menopause for more than one year.(for female subjects) 11: Must adopt isolation contraception measures within 3 months after the start of this study.(for female subjects) 12: Willing and capable to cooperate with all projects of this study. Exclusion Criteria: * 1: Other severe neurological disorders. Gastrointestinal, cardiovascular, liver, kidney, hematological, tumor, endocrine, respiratory, immunodeficiency, and other serious diseases. 2: Received ionizing radiation outside the scope of this experiment, resulting in an annual radiation exposure dose exceeding 50 mSv in the past year, 3: History of drug abuse or alcoholism 4: Pregnant or lactating women 5: Poor venous conditions, unable to tolerate repeated venipuncture 6: Received experimental drug or device treatment with unclear efficacy or safety in last 1 month. 7: Any situation that the investigators believe may cause harm or potential harm in any aspect related to this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple system atrophy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Walking memory tests may reveal early Parkinson's clues
- Colon tissue may hold clues to telling Parkinson's apart from Look-Alike diseases
- Can early markers predict how atypical Parkinson's diseases progress?
- AI hunts for early clues to Parkinson's and Alzheimer's progression
- Can 30,000 patients reveal Parkinson's hidden patterns?